Have A Little Faith in Gilead (GILD), Says Maxim Group

Gilead (GILD) Target Lowered to $125 at Deutsche Bank on Price War Concerns

Deutsche Bank maintained a Buy rating on Gilead Sciences (NASDAQ: GILD) and reduced its price target to $125.00 (from $142.00). Shares declined yesterday after Express Scripts (NASDAQ: ESRX) said they will only cover AbbVie''s (NYSE: ABBV) HCV therapy, Viekira Pak. Analyst Robyn Karnauskas said a price war changes dynamics in the HCV market.

"Express scripts decision to block Harvoni in GT-1 pts completely has... More

Express Scripts Decision in Hepatitis C Hints at Biosimilar Price War, Says Analyst (ABBV) (ESRX) (GILD)

Express Scripts (NASDAQ: ESRX) announcement that Abbvie's (NYSE: ABBV) Viekira will be the exclusive option for genotype 1 Hepatitis C patients could point to a future biosimilar price war, said Deutsche Bank analyst Robyn Karnauskas.

"We... More

Gilead Sciences (GILD) Sell-Off is an Overreaction, Baird Said; Doesn't See All Out Price War

Baird analyst Brian Skorney was the latest to weigh in on Gilead Sciences (NASDAQ: GILD) after Abbvie (NYSE: ABBV) and Express Scripts (NASDAQ: ESRX) reached an agreement to put Viekira on the national formulary for Hep C and drop Gilead

"Although not unexpected, we do see this... More

Gilead (GILD) Sell-Off Seen as Opportunity at Wells Fargo

Wells Fargo called today's sell-off in Gilead Sciences (NASDAQ: GILD) an opportunity. The decline follows news Express Scripts (NASDAQ: ESRX) selected AbbVie's (NYSE: ABBV) Viekira Pak as its exclusive treatment... More

Buy Gilead Sciences (GILD) on Weakness, BMO Capital Says; PT Dropped $20 on News

BMO Capital analyst Jim Birchenough dropped his price target on Gilead Sciences (NASDAQ: GILD) to $150.00 (from $170.00) after assessing the impact of Express Scripts' (NASDAQ: ESRX) move make GILD competitor AbbVie's (NYSE: ABBV) VIEKIRA... More

Express Scripts/AbbVie Deal a 'Double Whammy' for Gilead Sciences (GILD); Deal Could Have Sector Wide Repercussions

JPMorgan analyst Cory Kasimov weighed in on Gilead Sciences (NASDAQ: GILD), which is down 13.7% after Express Scripts (NASDAQ: ESRX) announced a exclusive multi-year agreement with AbbVie (NYSE: ABBV) to make Viekira Pak the exclusive option for GT1 patients covered by its National Preferred... More

Deutsche Bank Comments on Gilead (GILD); CVS Health (CVS) Could Be Next to Decide on Formulary

Deutsche Bank analyst Robyn Karnauskas commented on Gilead Sciences (NASDAQ: GILD) in a research note Monday. The stock dropped 11% after Express Scripts (NASDAQ: ESRX) said AbbVie's (NYSE: ABBV) Viekira Pak will be the exclusive option for genotype 1 Hepatitis C patients covered by the express scripts national preferred formulary.

"ESRX covers 85-90M lives in the US and this decision applies to 25M lives which are covered under commercial program. ESRX noted that... More

Gilead (GILD) Tanks; Analyst Comments on Express Scripts (ESRX) Viekira Pak Announcement (ABBV)

Shares of Gilead Sciences (NASDAQ: GILD) declined premarket Monday after Express Scripts (NASDAQ: ESRX) said AbbVie's (NYSE: ABBV) Viekira Pak will be the exclusive option for genotype 1 Hepatitis C patients covered by the express scripts national preferred formulary.

Commenting on developments,... More

AbbVie (ABBV): Express Scripts (ESRX) Says Viekira Pak Will Be the Exclusive Option for Genotype 1 Hepatitis C Patients (GILD)

Offering an unprecedented solution to an unprecedented healthcare challenge, Express Scripts (NASDAQ: ESRX) today announced an update to its National Preferred Formulary that will significantly expand access to AbbVie's (NYSE: ABBV) new medication, Viekira Pak®,a breakthrough treatment for hepatitis C.

Viekira Pak, approved by the U.S. Food and Drug Administration on December 19, was determined to be at least clinically equivalent to Harvoni® (ledipasvir and sofosbuvir) and Sovaldi® (sofosbuvir) by Express Scripts' independent Pharmacy & Therapeutics Committee. As a result of the committee's determination, Viekira Pak... More

Express Scripts (ESRX), AbbVie (ABBV) Enter Agreement for Recently-Approved Viekira Pak

Express Scripts (Nasdaq: ESRX) announced an update to its National Preferred Formulary that will significantly expand access to AbbVie's (NYSE: ABBV) new medication, Viekira Pak®, a breakthrough treatment for hepatitis C.

Viekira Pak, approved by the U.S. Food and Drug Administration on December 19, was determined to be at least clinically equivalent to Gilead's (Nasdaq: GILD) Harvoni (ledipasvir and sofosbuvir) and Sovaldi (sofosbuvir) by Express Scripts' independent Pharmacy & Therapeutics Committee. As a result of the committee's determination, Viekira Pak will... More